Open Questions: Mechanisms

Ranked research questions extracted from wiki pages and knowledge gaps
Field: GenesProteinsMechanismsTherapeuticsDiseasesPathwaysCell TypesBrain RegionsMethods
Sort by: Importance Elo Potential Impact Tractability
200 questions found for field 'Mechanisms'
open ⚖ 1500
Are there safety concerns about enhancing synaptic adhesion in a system where over-connectivity could promote excitotoxicity?
📑 0.50 💥 0.50
open ⚖ 1500
Can NRXN-NLGN dysfunction be detected presymptomatically, enabling preventive intervention?
📑 0.50 💥 0.50
open ⚖ 1500
What is the optimal approach: enhancing existing complexes, replacing lost components, or building artificial bridges?
📑 0.50 💥 0.50
open ⚖ 1500
Cell-type specificity** — Can we achieve neuron-specific targeting?
📑 0.50 💥 0.50
open ⚖ 1500
Can we develop therapies that selectively target pathological condensates?
📑 0.50 💥 0.50
open ⚖ 1500
What determines the transition from physiological to pathological phase separation?
📑 0.50 💥 0.50
open ⚖ 1500
Combination therapy:** Optimal partners?
📑 0.50 💥 0.50
open ⚖ 1500
Therapeutic timing:** When is intervention most effective?
📑 0.50 💥 0.50
open ⚖ 1500
Cellular context**: What determines microglial response?
📑 0.50 💥 0.50
open ⚖ 1500
Novel anticholinergics
📑 0.50 💥 0.50
open ⚖ 1500
Strain identification**: How do strains determine phenotypes?
📑 0.50 💥 0.50
open ⚖ 1500
Initiating events**: What triggers the first misfolding?
📑 0.50 💥 0.50
open ⚖ 1500
Are TLOs causative or consequential?
📑 0.50 💥 0.50
open ⚖ 1500
Can TLOs be reversed?
📑 0.50 💥 0.50
open ⚖ 1500
Can zombosomes be detected in cerebrospinal fluid or blood?
📑 0.50 💥 0.50
open ⚖ 1500
Is it specific to certain astrocyte subtypes?
📑 0.50 💥 0.50
open ⚖ 1500
What cellular stress signals are required?
📑 0.50 💥 0.50
open ⚖ 1500
Why are dopaminergic neurons particularly vulnerable?
📑 0.50 💥 0.50
open ⚖ 1500
Temporal dynamics** — When does HS3ST2 upregulation occur relative to tau pathology?
📑 0.50 💥 0.50
open ⚖ 1500
Which microglial states are causally protective versus harmful at each disease stage?
📑 0.50 💥 0.50
open ⚖ 1500
Combination Strategies**: Which pharmacological agents synergize with exercise?
📑 0.50 💥 0.50
open ⚖ 1500
How should human trials operationalize tripartite endpoints beyond global cognition scales?
📑 0.50 💥 0.50
open ⚖ 1500
Development**: What drives meningeal lymphatic development?
📑 0.50 💥 0.50
open ⚖ 1500
Regulation**: How are lymphatics regulated in the CNS?
📑 0.50 💥 0.50
open ⚖ 1500
Why do different diseases have different patterns?
📑 0.50 💥 0.50
open ⚖ 1500
Can propagation be stopped once started?
📑 0.50 💥 0.50
open ⚖ 1500
What determines PSP-C vs. Richardson syndrome phenotype?
📑 0.50 💥 0.50
open ⚖ 1500
Timing**: When in disease course?
📑 0.50 💥 0.50
open ⚖ 1500
Cell type**: Which cells drive changes?
📑 0.50 💥 0.50
open ⚖ 1500
Therapeutic window**: When in disease course is intervention most effective?
📑 0.50 💥 0.50
open ⚖ 1500
Cell-type specificity**: What makes certain neurons more vulnerable?
📑 0.50 💥 0.50
open ⚖ 1500
Primary vs. secondary excitotoxicity**: Is excitotoxicity a primary driver or downstream effect?
📑 0.50 💥 0.50
open ⚖ 1500
Genetic stratification
📑 0.50 💥 0.50
open ⚖ 1500
How do age-related changes in neurexin expression interact with protein aggregation pathologies in sporadic neurodegeneration?
📑 0.50 💥 0.50
open ⚖ 1500
Which specific neurexin splice isoforms are most dysregulated in each neurodegenerative disease, and can we selectively restore them?
📑 0.50 💥 0.50
open ⚖ 1500
Fission vs. fusion prioritization** — Which process is more critical to target?
📑 0.50 💥 0.50
open ⚖ 1500
Optimal intervention timing** — When during disease progression should fission be modulated?
📑 0.50 💥 0.50
open ⚖ 1500
Why are specific neurons vulnerable?
📑 0.50 💥 0.50
open ⚖ 1500
How do other PD genes (LRRK2, GBA, SNCA) interact with the DJ-1-PTEN-P53 network?
📑 0.50 💥 0.50
open ⚖ 1500
What is the role of neuronal activity-dependent oxidative stress in modulating this network?
📑 0.50 💥 0.50
open ⚖ 1500
Can we develop therapies that selectively enhance the PTEN-activating function of DJ-1 without affecting P53 stabilization?
📑 0.50 💥 0.50
open ⚖ 1500
What determines the threshold between protective and destructive P53 activation?
📑 0.50 💥 0.50
open ⚖ 1500
How do different cell types in the brain contribute to condensate pathology?
📑 0.50 💥 0.50
open ⚖ 1500
What is the exact relationship between phase separation and traditional protein aggregation?
📑 0.50 💥 0.50
open ⚖ 1500
Signaling specificity:** How is pathway specificity achieved?
📑 0.50 💥 0.50
open ⚖ 1500
Ligand identification:** Complete ligand repertoire?
📑 0.50 💥 0.50
open ⚖ 1500
Off-target effects**: How to minimize impact on kidney and lung function?
📑 0.50 💥 0.50
open ⚖ 1500
Non-motor symptoms**: Does LRRK2 inhibition help constipation, sleep disorders, anosmia?
📑 0.50 💥 0.50
open ⚖ 1500
Combination**: Should LRRK2 inhibitors combine with anti-alpha-synuclein therapies?
📑 0.50 💥 0.50
open ⚖ 1500
Timing**: Pre-symptomatic vs. symptomatic intervention — which is more effective?
📑 0.50 💥 0.50
open ⚖ 1500
Population selection**: Should therapy target all PD, only LRRK2 mutation carriers, or all with elevated LRRK2 activity?
📑 0.50 💥 0.50
open ⚖ 1500
Optimal dosing**: What level of kinase inhibition is needed vs. tolerated?
📑 0.50 💥 0.50
open ⚖ 1500
Cell-type specificity:
📑 0.50 💥 0.50
open ⚖ 1500
Temporal dynamics:
📑 0.50 💥 0.50
open ⚖ 1500
Species differences:
📑 0.50 💥 0.50
open ⚖ 1500
Target validation:
📑 0.50 💥 0.50
open ⚖ 1500
Therapeutic window:
📑 0.50 💥 0.50
open ⚖ 1500
Combination approaches:
📑 0.50 💥 0.50
open ⚖ 1500
Single-cell proteomics:
📑 0.50 💥 0.50
open ⚖ 1500
What are optimal therapeutic targets?
📑 0.50 💥 0.50
open ⚖ 1500
Can antiretroviral therapy meaningfully impact disease?
📑 0.50 💥 0.50
open ⚖ 1500
What triggers HERV activation in disease?
📑 0.50 💥 0.50
open ⚖ 1500
Which HERV elements are truly pathogenic?
📑 0.50 💥 0.50
open ⚖ 1500
Cell-type mechanisms**: How does the same axis produce opposite effects in neurons versus glia?
📑 0.50 💥 0.50
open ⚖ 1500
Temporal dynamics**: When does axis dysregulation begin relative to tau pathology?
📑 0.50 💥 0.50
open ⚖ 1500
Personalized dosing
📑 0.50 💥 0.50
open ⚖ 1500
Causality**: Does ETC dysfunction initiate or result from neurodegeneration?
📑 0.50 💥 0.50
open ⚖ 1500
What determines the balance between amyloidogenic and non-amyloidogenic APP processing in neurons?
📑 0.50 💥 0.50
open ⚖ 1500
Combination approaches**: Optimal treatment combinations?
📑 0.50 💥 0.50
open ⚖ 1500
How does Fe65 phosphorylation regulate complex formation in vivo?
📑 0.50 💥 0.50
open ⚖ 1500
Therapeutic window**: What level of GCase restoration is needed?
📑 0.50 💥 0.50
open ⚖ 1500
Can we develop substrate-selective inhibitors that spare essential BACE1 functions?
📑 0.50 💥 0.50
open ⚖ 1500
Penetrance modifiers**: What determines which carriers develop PD?
📑 0.50 💥 0.50
open ⚖ 1500
What is the complete inventory of BACE1 substrates, and how does chronic inhibition affect their function?
📑 0.50 💥 0.50
open ⚖ 1500
Therapeutic window**: What is the optimal activation level?
📑 0.50 💥 0.50
open ⚖ 1500
How do TNTs interact with other transfer mechanisms?**: What is the relationship between TNTs and extracellular vesicles?
📑 0.50 💥 0.50
open ⚖ 1500
What determines TNT specificity?**: Why do some cells form TNTs while others do not?
📑 0.50 💥 0.50
open ⚖ 1500
Therapeutic translation**: Can preclinical findings be successfully translated into effective clinical therapies?
📑 0.50 💥 0.50
open ⚖ 1500
Interrelationship with other proteinopathies**: How does TDP-43 pathology interact with other pathological proteins (tau, alpha-synuclein)?
📑 0.50 💥 0.50
open ⚖ 1500
Strain heterogeneity**: How do distinct TDP-43 conformational strains influence clinical phenotypes?
📑 0.50 💥 0.50
open ⚖ 1500
Immunotherapies
📑 0.50 💥 0.50
open ⚖ 1500
Oligomer breakers
📑 0.50 💥 0.50
open ⚖ 1500
Cell replacement
📑 0.50 💥 0.50
open ⚖ 1500
Mechanisms of aggregation initiation**: What triggers the initial misfolding and aggregation of TDP-43 in sporadic cases?
📑 0.50 💥 0.50
open ⚖ 1500
mtDNA editing
📑 0.50 💥 0.50
open ⚖ 1500
Gene therapy
📑 0.50 💥 0.50
open ⚖ 1500
Combination Therapy
📑 0.50 💥 0.50
open ⚖ 1500
Multi-omics integration
📑 0.50 💥 0.50
open ⚖ 1500
Optimal intervention timing?
📑 0.50 💥 0.50
open ⚖ 1500
Mechanistic Studies
📑 0.50 💥 0.50
open ⚖ 1500
Tau cryo-EM
📑 0.50 💥 0.50
open ⚖ 1500
Synthetic biology
📑 0.50 💥 0.50
open ⚖ 1500
Therapeutic targeting
📑 0.50 💥 0.50
open ⚖ 1500
Gene therapy
📑 0.50 💥 0.50
open ⚖ 1500
Neuromodulation
📑 0.50 💥 0.50
open ⚖ 1500
Phenotype-stratified
📑 0.50 💥 0.50
open ⚖ 1500
Biomarker-driven
📑 0.50 💥 0.50
open ⚖ 1500
What determines TNT specificity?
📑 0.50 💥 0.50
open ⚖ 1500
Can TNTs be therapeutically targeted?
📑 0.50 💥 0.50
open ⚖ 1500
Single-cell TNT analysis
📑 0.50 💥 0.50
open ⚖ 1500
In vivo TNT visualization
📑 0.50 💥 0.50
open ⚖ 1500
TNT-based therapeutics
📑 0.50 💥 0.50
open ⚖ 1500
Multi-cohort validation
📑 0.50 💥 0.50
open ⚖ 1500
CLIA-validated assays
📑 0.50 💥 0.50
open ⚖ 1500
Gene Therapy
📑 0.50 💥 0.50
open ⚖ 1500
Signaling nuances**: How does DAP12 signal specificity work?
📑 0.50 💥 0.50
open ⚖ 1500
Exact ligand**: What is the primary physiological ligand?
📑 0.50 💥 0.50
open ⚖ 1500
Biomarker validation**: Which markers predict progression?
📑 0.50 💥 0.50
open ⚖ 1500
Therapeutic windows**: When is intervention most effective?
📑 0.50 💥 0.50
open ⚖ 1500
Clearance mechanisms**: Why does clearance fail?
📑 0.50 💥 0.50
open ⚖ 1500
SCN-specific tau vulnerability**: What makes SCN neurons particularly susceptible to 4R tau?
📑 0.50 💥 0.50
open ⚖ 1500
Clock gene therapeutic targets**: Which clock genes are most druggable for CBD?
📑 0.50 💥 0.50
open ⚖ 1500
Microglial circadian rhythms**: How do microglial rhythms affect neuroinflammation in CBD?
📑 0.50 💥 0.50
open ⚖ 1500
Sex differences** — Are there gender-specific effects on the axis?
📑 0.50 💥 0.50
open ⚖ 1500
Which therapeutic approach is optimal?
📑 0.50 💥 0.50
open ⚖ 1500
What is the primary trigger of mitochondrial dysfunction in sporadic PD?
📑 0.50 💥 0.50
open ⚖ 1500
OPC transplantation
📑 0.50 💥 0.50
open ⚖ 1500
iPSC-derived neurons
📑 0.50 💥 0.50
open ⚖ 1500
Immunomodulatory approaches
📑 0.50 💥 0.50
open ⚖ 1500
What are the long-term effects of chelation?
📑 0.50 💥 0.50
open ⚖ 1500
Protein degrons
📑 0.50 💥 0.50
open ⚖ 1500
RNA splicing modulators
📑 0.50 💥 0.50
open ⚖ 1500
Intrabodies
📑 0.50 💥 0.50
open ⚖ 1500
Cell therapy
📑 0.50 💥 0.50
open ⚖ 1500
Phase I/II clinical trials
📑 0.50 💥 0.50
open ⚖ 1500
Novel drug delivery
📑 0.50 💥 0.50
open ⚖ 1500
Combination therapies
📑 0.50 💥 0.50
open ⚖ 1500
Gene therapy
📑 0.50 💥 0.50
open ⚖ 1500
Biomarker development
📑 0.50 💥 0.50
open ⚖ 1500
Microbiome modulation
📑 0.50 💥 0.50
open ⚖ 1500
Multi-omics integration
📑 0.50 💥 0.50
open ⚖ 1500
Single-cell PTM analysis
📑 0.50 💥 0.50
open ⚖ 1500
PTM cross-talk
📑 0.50 💥 0.50
open ⚖ 1500
Biomarker validation
📑 0.50 💥 0.50
open ⚖ 1500
Mechanism Integration
📑 0.50 💥 0.50
open ⚖ 1500
Biomarker Validation
📑 0.50 💥 0.50
open ⚖ 1500
Therapeutic Translation
📑 0.50 💥 0.50
open ⚖ 1500
Genetic Counseling
📑 0.50 💥 0.50
open ⚖ 1500
Biomarker development
📑 0.50 💥 0.50
open ⚖ 1500
Spatial transcriptomics
📑 0.50 💥 0.50
open ⚖ 1500
Network analysis
📑 0.50 💥 0.50
open ⚖ 1500
Mathematical models
📑 0.50 💥 0.50
open ⚖ 1500
Integration
📑 0.50 💥 0.50
open ⚖ 1500
Biomarker validation
📑 0.50 💥 0.50
open ⚖ 1500
Patient selection
📑 0.50 💥 0.50
open ⚖ 1500
Trial design
📑 0.50 💥 0.50
open ⚖ 1500
Structural biology
📑 0.50 💥 0.50
open ⚖ 1500
iPSC models
📑 0.50 💥 0.50
open ⚖ 1500
Combination therapies
📑 0.50 💥 0.50
open ⚖ 1500
Oral semaglutide
📑 0.50 💥 0.50
open ⚖ 1500
Depot formulations
📑 0.50 💥 0.50
open ⚖ 1500
Intranasal delivery
📑 0.50 💥 0.50
open ⚖ 1500
GLP-1 + GIP
📑 0.50 💥 0.50
open ⚖ 1500
GLP-1 + anti-amyloid
📑 0.50 💥 0.50
open ⚖ 1500
GLP-1 + neurotrophic factors
📑 0.50 💥 0.50
open ⚖ 1500
Pharmacogenomics
📑 0.50 💥 0.50
open ⚖ 1500
Biomarker stratification
📑 0.50 💥 0.50
open ⚖ 1500
Disease staging
📑 0.50 💥 0.50
open ⚖ 1500
Mechanism of Transfer
📑 0.50 💥 0.50
open ⚖ 1500
Therapeutic Target
📑 0.50 💥 0.50
open ⚖ 1500
Clinical Translation
📑 0.50 💥 0.50
open ⚖ 1500
TREM2 and gut-brain axis
📑 0.50 💥 0.50
open ⚖ 1500
Ligand discrimination
📑 0.50 💥 0.50
open ⚖ 1500
Spatial organization
📑 0.50 💥 0.50
open ⚖ 1500
Temporal dynamics
📑 0.50 💥 0.50
open ⚖ 1500
Cell type specificity
📑 0.50 💥 0.50
open ⚖ 1500
TREM2 and aging
📑 0.50 💥 0.50
open ⚖ 1500
TREM2 in psychiatric disorders
📑 0.50 💥 0.50
open ⚖ 1500
Epigenetic regulation
📑 0.50 💥 0.50
open ⚖ 1500
Receptor activation:
📑 0.50 💥 0.50
open ⚖ 1500
Biomarker development:
📑 0.50 💥 0.50
open ⚖ 1500
Spatial transcriptomics:
📑 0.50 💥 0.50
open ⚖ 1500
Organoid models:
📑 0.50 💥 0.50
open ⚖ 1500
Gene editing:
📑 0.50 💥 0.50
open ⚖ 1500
Single-cell analysis
📑 0.50 💥 0.50
open ⚖ 1500
Spatial transcriptomics
📑 0.50 💥 0.50
open ⚖ 1500
CRISPR screens
📑 0.50 💥 0.50
open ⚖ 1500
What triggers initial alpha-synuclein misfolding in oligodendrocytes?
📑 0.50 💥 0.50
open ⚖ 1500
Why are specific oligodendrocyte populations vulnerable?
📑 0.50 💥 0.50
open ⚖ 1500
What determines the clinical phenotype (MSA-P vs. MSA-C)?
📑 0.50 💥 0.50
open ⚖ 1500
Can GCI formation be prevented or reversed?
📑 0.50 💥 0.50
open ⚖ 1500
What is the relationship between neuronal and oligodendrocyte pathology?
📑 0.50 💥 0.50
open ⚖ 1500
Biomarker-guided trials
📑 0.50 💥 0.50
open ⚖ 1500
Gene therapy
📑 0.50 💥 0.50
open ⚖ 1500
α-Synuclein seeding assays
📑 0.50 💥 0.50
open ⚖ 1500
Neuroimaging advances
📑 0.50 💥 0.50
open ⚖ 1500
Wearable devices
📑 0.50 💥 0.50
open ⚖ 1500
Multi-modal biomarkers
📑 0.50 💥 0.50
open ⚖ 1500
Mitochondrial replacement therapy
📑 0.50 💥 0.50
open ⚖ 1500
Small molecule
📑 0.50 💥 0.50
open ⚖ 1500
M stable dopaminergic compounds
📑 0.50 💥 0.50
open ⚖ 1500
Genetic testing
📑 0.50 💥 0.50
open ⚖ 1500
Biomarker monitoring
📑 0.50 💥 0.50
open ⚖ 1500
Patient-specific
📑 0.50 💥 0.50
open ⚖ 1500
Precision targeting
📑 0.50 💥 0.50
open ⚖ 1500
Temporal Dynamics
📑 0.50 💥 0.50
open ⚖ 1500
Cell Type Specificity
📑 0.50 💥 0.50
open ⚖ 1500
Single-Cell Analysis
📑 0.50 💥 0.50
open ⚖ 1500
Spatial Transcriptomics
📑 0.50 💥 0.50
open ⚖ 1500
Therapeutic**: Optimal intervention point?
📑 0.50 💥 0.50

🌱 Cross-Pollination

Fields that illuminate Mechanisms through bridging wiki connections. See all cross-field connections →

Cross-pollination from Researchers 5,611 bridges →
Cross-pollination from Institutions 7,270 bridges →
Cross-pollination from Technologies 8,040 bridges →
Open Questions | Part of the SciDEX Atlas layer | API | Cross-field map